Judge OKs landmark class action settlement in LGBTQ fertility lawsuit

Judge OKs landmark class action settlement in LGBTQ fertility lawsuit


A Pride flag is seen held up in a crowd during preparation for a Queer March to the Texas State Capitol on April 15, 2023 in Austin, Texas. People from across Texas rallied together in protest against a slew of anti-LGBTQIA+ and drag bills being proposed among legislators.

Brandon Bell | Getty Images

A federal judge approved a landmark class action settlement this week between Aetna and same-sex couples in New York who alleged the insurance behemoth had discriminated against them and other LGBTQ customers seeking fertility treatment.

Aetna, a subsidiary of CVS Health Corp., reached a deal with the couples in October to begin covering artificial insemination for all of its customers nationally and work toward providing equal access for costly in-vitro fertilization procedures. 

The judge’s sign-off on the settlement marks the first time LGBTQ couples who were previously denied fertility coverage in the U.S. can apply to be reimbursed.

Emma Goidel and her spouse, Ilana Caplan, filed a lawsuit against Aetna in 2021 after the health insurer denied several of their requests for covering their fertility treatments. The couple, who were represented by the National Women’s Law Center, said they spent more than $50,000 out of pocket to conceive their second child.

“LGBTQ+ folks are as deserving of becoming parents as anyone else on this planet,” Goidel said. “I hope that when people can start signing up to be compensated, queer folks who have gone on the journey to become parents and faced barriers from insurance feel that they’re not alone in that.”  

Aetna declined to comment. A spokesperson for CVS Health Corp. previously said the company was pleased to resolve the case and was “committed to providing quality care to all individuals regardless of their sexual orientation or gender identity.”

Thirteen states require insurers to cover fertility treatments for same-sex couples who cannot conceive on their own, according to RESOLVE, a national infertility association. However, the law exempts companies that have self-funded insurance policies, where employers directly pay for employee claims.

“It is really uncomfortable sometimes to talk to your employer or your HR department about what benefits are offered, especially when those benefits have to do with wanting to start a family,” said Allison Tanner, an attorney for the National Women’s Law Center.

Similar cases have been filed against other insurance giants, including UnitedHealthcare and Blue Cross Blue Shield. Those companies did not immediately return requests for comment on Aetna’s settlement.



Source

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Health

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020. Mike Blake | Reuters Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 […]

Read More
Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
Health

Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in […]

Read More
Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Health

Eli Lilly earnings are coming Thursday. Here’s what top analysts expect

Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]

Read More